BNTC vs BTAI

Benitec Biopharma Inc. vs BioXcel Therapeutics, Inc. — Valuation Comparison 2026

BNTC

Pharmaceutical Preparations
Benitec Biopharma Inc.
Quality
4.4
out of 10
Value Trap
45
WARN
Price
$11.56
Last close
Models
7/13
Active
VS

BTAI

Pharmaceutical Preparations
BioXcel Therapeutics, Inc.
Quality
4.4
out of 10
Value Trap
24
SAFE
Price
$1.17
Last close
Models
4/13
Active

Model-by-Model Comparison

ModelType BNTC Fair ValueBNTC Upside BTAI Fair ValueBTAI Upside
Bayesian DCF Intrinsic $5.90 -49.0%
EROIC Spread Intrinsic $1.49 +24.3%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $5.93 -48.7%
PWERM Option-Based $10.27 -11.2% $3.95 +237.3%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for BNTC vs BTAI — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

BNTC vs BTAI — Which Stock Is More Undervalued?

BNTC scores higher with a 4.4/10 quality rating vs BTAI's 4.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Benitec Biopharma Inc. (BNTC) and BioXcel Therapeutics, Inc. (BTAI) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

BNTC currently trades at $11.56 with a QOC of 4.4/10, while BTAI trades at $1.17 with a QOC of 4.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).